



ATTORNEY'S DOCKET NO.: 2003080-0054 (SK-893-US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Danishefsky *et al.* Examiner : Canella, Karen A.  
Serial No. : 09/641,742 Art Unit : 1642  
Filed : August 18, 2000  
For : *Novel Glycoconjugates, Glycoamino Acids, Intermediates Thereto, and  
Uses Thereof*

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants request consideration of this Supplemental Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

(Select A, B or C below)

A. ☒ This Supplemental Information Disclosure Statement has been filed

(check 1, 2 and/or 3 below)

1. ☐ within three months of the filing date of the above identified U.S. Patent application.
2. ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International application.
3. ☒ before the mailing date of the first Office Action on the merits in the above-identified application.
4. ☐ before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

No fee or certification is required.

B. ☐ This Supplemental Information Disclosure Statement has been filed more than three months after the filing date of the present application and after the mailing date of this first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311.

(check 1 or 2 below)

1. ☐ The fee of \$240 as set forth in 37 C.F.R. §1.17(p) is enclosed.
2. ☐ The Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that

(check a or b below)

- a. ☐ each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application not more than three months prior to the filing of this Statement.
- b. ☐ no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.

C. ☐ This Supplemental Information Disclosure Statement has been filed after the mailing date of either a Final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311 and before payment of an Issue Fee.

(check a or b below)

1. The Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that:
  - a. ☐ each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application not more than three months prior to the filing of this Statement.
  - b. ☐ no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual

designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.

2. A Petition requesting consideration of the Supplemental Information Disclosure Statement is attached.
3. The Petition Fee of \$130 as set forth in 37 C.F.R. §1.17(i)(1) is enclosed.

PART II - 37 CFR § 1.98 Content of Supplemental Information Disclosure Statement:

[X] Applicants hereby make of record in the above-identified application all patents, publications, applications or other information submitted for consideration by the Office listed on the attached form PTO-1449 (modified). The order of presentation of the patents, publications, applications or other information should not be construed as an indication of the importance.

For each patent, publication, or other information listed that is not in the English language, the following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

Alternatively, if a written English-language translation of a non-English-language document, or portion thereof, if within the possession, or control of, or is readily available to any individual designated in § 1.56(c), a copy of the translation is provided herein as identified:

PART III: Remarks

A copy of each of the above-identified U.S. and foreign patent(s), publication(s), application(s) or other information submitted is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s), publication(s), application(s), or other information be printed on any patent which issues from this application.

By submitting this Supplemental Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more material information may not exist.

By submitting this Supplemental Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Supplemental Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited materials. An early and favorable action is hereby requested.

Please charge required fees to Deposit Account No. 03-1721.

Respectfully submitted,

*Karoline K. M. Shair*

Karoline K. M. Shair, Ph.D.

Reg. No. 44,332



Choate, Hall & Stewart  
Exchange Place  
53 State Street  
Boston, MA 02109  
(617) 248-5000  
Date: April 12, 2002

CERTIFICATE OF FACSIMILE TRANSMISSION  
PURSUANT TO 1096 OG 30-31  
I hereby certify that this paper is being  
facsimile transmitted to the Assistant  
Commissioner For Patents, Washington,  
DC 20231  
on April 12, 2002  
Richard H. Pagan

Form PTO-1449  
(REV. 8-83)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
2003080-0054  
(SK-893-US)

In re Application No.  
09/641,742

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant: Danishefsky *et al.*

Filing Date:  
August 18, 2000

Group:  
1642

**U. S. PATENT DOCUMENTS**

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	5,683,674	Taylor-Papadimitriou <i>et al.</i>	Nov. 4, 1997	424	1.49
	6,222,020	Taylor-Papadimitriou <i>et al.</i>	April 24, 2001	530	395

**U.S. PATENT APPLICATIONS**

Examiner's Initials	Serial No.	Applicant	Filing Date		

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

Examiner's  
Initials

**OTHER DOCUMENTS  
(Including Author, Title, Date, Pertinent Pages, Etc.)**

	Zhang <i>et al.</i> , "Immune Sera and Monoclonal Antibodies Define Two Configurations for the Sialyl Tn Tumor Antigen", <i>Cancer Res.</i> <b>1995</b> , 55, 3364-3368.
	Toyokuni <i>et al.</i> , "Synthetic Carbohydrate Vaccines: Synthesis and Immunogenicity of Tn Antigen Conjugates", <i>Bioorg. Med. Chem.</i> <b>1994</b> , 2, 1119-1132

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.